A Prospective Study to Evaluate the Efficacy and Safety of MZL-IPI Risk-adapted Targeted Therapy in Patients With Untreated Marginal Zone B-cell Lymphoma
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Obinutuzumab (Primary) ; Orelabrutinib (Primary) ; Lenalidomide
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms MAGIC
- 03 Feb 2025 New trial record